Therapy of XDR TB with Thioridazine a Drug Beyond Patent Protection but Eligible for Patent “As New Use”

E-ISSN： 2212-4071|5|2|109-114

ISSN： 1574-891X

Source： Recent Patents on Anti-Infective Drug Discovery, Vol.5, Iss.2, 2010-06, pp. : 109-114

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and Efficacy of Thioridazine as Salvage Therapy in Indian Patients with XDR-TB

Recent Patents on Anti-Infective Drug Discovery, Vol. 6, Iss. 2, 2011-05 ,pp. : 88-91

Bentham Science Publishers

Access to resources Recommend Favorite

Streptokinase-A Drug for Thrombolytic Therapy: A Patent Review

Recent Patents on Cardiovascular Drug Discovery, Vol. 9, Iss. 2, 2014-12 ,pp. : 106-121

Bentham Science Publishers

Access to resources Recommend Favorite

The Relevance of New Drug Combinations for Modern Tuberculosis Treatment - A Patent Perspective

Recent Patents on Anti-Infective Drug Discovery, Vol. 8, Iss. 2, 2013-08 ,pp. : 130-138

Bentham Science Publishers

Access to resources Recommend Favorite

The Mechanism by which the Phenothiazine Thioridazine Contributes to Cure Problematic Drug-Resistant Forms of Pulmonary Tuberculosis: Recent Patents for “New Use”

Recent Patents on Anti-Infective Drug Discovery, Vol. 8, Iss. 3, 2013-01 ,pp. : 206-212

Bentham Science Publishers

Access to resources Recommend Favorite

Stem Cells in MDR-TB and XDR - TB

Current Respiratory Medicine Reviews, Vol. 10, Iss. 4, 2014-12 ,pp. : 238-240

Bentham Science Publishers

Access to resources Recommend Favorite